All In MedTech

Device Trial Radar · NCT05554471

Evaluation of Safety and Efficacy of the Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression

A Multicenter, Prospective, Randomized, Controlled, Open Label Trial to Evaluate the Safety and Efficacy of Mynx Control Venous Vascular Closure Device 6F-12F vs Manual Compression in Patients Who Have Undergone Endovascular Procedures Utilizing up to 12F Procedural Sheaths

Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 352 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

352

Actual

Start

Aug 30, 2022

Primary completion

Jul 11, 2023

Study completion Jul 11, 2023

Sponsor

Lead sponsor
Cordis US Corp.Not on our public-company list
Sponsor type
Industry
Collaborators
NAMSA
First posted
Sep 26, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ReliaSeal is a clinical trial designed to evaluate safety and efficacy of use of MYNX CONTROL™ Venous Vascular Closure Device 6F-12F vs. manual compression to seal femoral access sites in patients who have undergone endovascular procedures utilizing up to 12F procedural sheaths in one or both limbs.

Conditions

  • Venous Vascular Closure

Interventions

  • MYNX CONTROL™ Venous Vascular Closure Device 6F-12FDevice

    Mynx Control Venous VCD 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Safety Endpoint: Major Complications of the Target Limb Access Site Within 30 DaysTime frame: 30 days post procedure
  2. Primary Effectiveness Endpoint: Time to AmbulationTime frame: Post procedure
  3. Primary Effectiveness Endpoint: Time to HemostasisTime frame: Post procedure

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Arizona Cardiovascular Research Center

    Phoenix, Arizona

  • Colorado Heart and Vascular PC

    Lakewood, Colorado

  • Baptist Health Miami Cardiac and Vascular Institute

    Miami, Florida

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.